Despite only coming into life two years ago, Pfizer and NEA-backed upstart Vtesse has already seen its rare disease candidate VTS-270, for Niemann-Pick disease type C1, nab the coveted FDA breakthrough tag, and has now been bought out by Maryland-based biotech Sucampo.
The deal sees the biopharma pay $200 million upfront in cash and stock, with the pair also seeking to set up a new foundation, after the deal is signed, “to support research related to NPC disease.” Both will pay into this new organization.
{iframe}http://www.fiercebiotech.com/node/478036{/iframe}